Literature DB >> 7500096

Clinical and [18F] dopa PET findings in early Parkinson's disease.

P K Morrish1, G V Sawle, D J Brooks.   

Abstract

Twenty seven patients with recent onset (mean symptom duration 22 (SD 14) months, Hoehn and Yahr score 1.8 (SD 0.7)) Parkinson's disease were studied with [18F]dopa PET. There was a correlation between putamen influx (Ki) and clinical rating, but not symptom duration. In 11 patients with hemi-Parkinson's disease of recent onset there were significant differences between normal (mean 0.0123 (SD 0.0023)), asymptomatic (mean 0.0099 (0.0020)) and symptomatic (mean 0.0070 (00.014)) putamen Kis. This suggests that Parkinson's disease has a widely variable rate of progression, and is most compatible with a short preclinical period. Symptom onset was estimated at a putamen Ki of between 57% and 80% of normal. Most ipsilateral putamen Ki values in early asymmetric Parkinson's disease fell within the normal range. The implication is that either the disease is not established in the ipsilateral putamen or that the technique is insufficiently sensitive to detect it. Discriminant analysis completely separated the normal and Parkinson's disease cohorts, but when a discriminant function from a previous study was used predictively four of the 27 patients with Parkinson's disease were incorrectly classified as normal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500096      PMCID: PMC1073753          DOI: 10.1136/jnnp.59.6.597

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects.

Authors:  B E Boyes; P Cumming; W R Martin; E G McGeer
Journal:  Life Sci       Date:  1986-12-08       Impact factor: 5.037

2.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

3.  Progression of unilateral tremor and rigidity in Parkinson's disease.

Authors:  R M Scott; J A Brody; R S Schwab; I S Cooper
Journal:  Neurology       Date:  1970-07       Impact factor: 9.910

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.

Authors:  G V Sawle; D J Burn; P K Morrish; A A Lammertsma; B J Snow; S Luthra; S Osman; D J Brooks
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

7.  Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.

Authors:  S Takikawa; V Dhawan; T Chaly; W Robeson; R Dahl; I Zanzi; F Mandel; P Spetsieris; D Eidelberg
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

8.  Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

Authors:  B J Snow; I Tooyama; E G McGeer; T Yamada; D B Calne; H Takahashi; H Kimura
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

9.  Striatal 18F-dopa uptake: absence of an aging effect.

Authors:  D Eidelberg; S Takikawa; V Dhawan; T Chaly; W Robeson; R Dahl; D Margouleff; J R Moeller; C S Patlak; S Fahn
Journal:  J Cereb Blood Flow Metab       Date:  1993-09       Impact factor: 6.200

10.  Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

Authors:  G V Sawle; E D Playford; D J Burn; V J Cunningham; D J Brooks
Journal:  Arch Neurol       Date:  1994-03
View more
  47 in total

Review 1.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 2.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

Review 3.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 4.  Dopamine overdose hypothesis: evidence and clinical implications.

Authors:  David E Vaillancourt; Daniel Schonfeld; Youngbin Kwak; Nicolaas I Bohnen; Rachael Seidler
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 5.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

6.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Authors:  J Booij; G Tissingh; G J Boer; J D Speelman; J C Stoof; A G Janssen; E C Wolters; E A van Royen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

7.  Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

Authors:  M E Emborg; J Moirano; J Raschke; V Bondarenko; R Zufferey; S Peng; A D Ebert; V Joers; B Roitberg; J E Holden; J Koprich; J Lipton; J H Kordower; P Aebischer
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

8.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

9.  Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.

Authors:  Y Murakami; S Kakeda; K Watanabe; I Ueda; A Ogasawara; J Moriya; S Ide; K Futatsuya; T Sato; K Okada; T Uozumi; S Tsuji; T Liu; Y Wang; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.